This trial is being conducted in Europe in healthy volunteers and is designed to help define dosing regimens to assess in patients with inflammatory diseases and cancer.
Daryl Winter, COO of Calistoga, said: “We believe this study will provide us the information needed to move our 2008/2009 clinical programs forward and begin multiple trials using compounds with different PI3K isoform selectivity profiles; each of which should a have unique profile tailored to specific diseases.”